S
Zodix
Study
Academic Library
Search
Shelves
Open access
Sign in
Search or jump to…
⌘K
Steven Simoens · Study
Home
/
Author
Steven Simoens
28 works
· latest 2021
· 2 institutions
cluster: provisional
ORCID 0000-0002-9512-2005
Follow
Suggest an ORCID correction
h-index
28
i10
28
Citations
3,179
Works here
28
06
07
09
10
11
12
13
14
15
17
18
19
21
Most cited in this library
Pricing and reimbursement of orphan drugs: the need for more transparency
2011 · 261 citations
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
2012 · 171 citations
Sustaining Generic Medicines Markets in Europe
2006 · 161 citations
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
2018 · 159 citations
Outrageous prices of orphan drugs: a call for collaboration
2018 · 158 citations
Works
28 shown
R&D Costs of New Medicines: A Landscape Analysis
Frontiers in Medicine
·
2021
·
2 authors
·
Open access
87
citations
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Expert Review of Pharmacoeconomics & Outcomes Research
·
2021
·
50 authors
·
Open access
75
citations
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
Frontiers in Pharmacology
·
2019
·
19 authors
·
Open access
75
citations
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
Frontiers in Public Health
·
2018
·
52 authors
·
review
·
Open access
159
citations
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review
Drug Discovery Today
·
2018
·
11 authors
·
review
·
Open access
91
citations
Outrageous prices of orphan drugs: a call for collaboration
The Lancet
·
2018
·
19 authors
158
citations
Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group
Value in Health
·
2018
·
11 authors
·
Open access
131
citations
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
Frontiers in Pharmacology
·
2018
·
44 authors
·
Open access
112
citations
The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
Frontiers in Pharmacology
·
2017
·
6 authors
·
Open access
104
citations
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
Frontiers in Pharmacology
·
2017
·
5 authors
·
Open access
142
citations
Toward a European definition for a drug shortage: a qualitative study
Frontiers in Pharmacology
·
2015
·
4 authors
·
Open access
72
citations
Insights into European Drug Shortages: A Survey of Hospital Pharmacists
PLoS ONE
·
2015
·
4 authors
·
Open access
132
citations
Causes of drug shortages in the legal pharmaceutical framework
Regulatory Toxicology and Pharmacology
·
2015
·
5 authors
·
Open access
86
citations
Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
BMC Health Services Research
·
2014
·
4 authors
·
Open access
128
citations
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
Journal of Comparative Effectiveness Research
·
2014
·
12 authors
·
Open access
73
citations
Demand-side policies to encourage the use of generic medicines: an overview
Expert Review of Pharmacoeconomics & Outcomes Research
·
2013
·
3 authors
87
citations
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Orphanet Journal of Rare Diseases
·
2013
·
7 authors
·
Open access
122
citations
Orphan Drugs for Rare Diseases
Drugs
·
2012
·
4 authors
74
citations
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Orphanet Journal of Rare Diseases
·
2012
·
3 authors
·
Open access
171
citations
Does the Market Share of Generic Medicines Influence the Price Level?
PharmacoEconomics
·
2011
·
2 authors
85
citations
Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?
Health Policy
·
2011
·
3 authors
98
citations
Pricing and reimbursement of orphan drugs: the need for more transparency
Orphanet Journal of Rare Diseases
·
2011
·
1 author
·
Open access
261
citations
A comparative study of European rare disease and orphan drug markets
Health Policy
·
2010
·
5 authors
121
citations
The costs of breast cancer prior to and following diagnosis
The European Journal of Health Economics
·
2010
·
9 authors
73
citations
Health Economic Assessment: A Methodological Primer
International Journal of Environmental Research and Public Health
·
2009
·
1 author
·
review
·
Open access
116
citations
International comparison of generic medicine prices
Current Medical Research and Opinion
·
2007
·
1 author
86
citations
Job Satisfaction and Quitting Intentions: A Structural Model of British General Practitioners
British Journal of Industrial Relations
·
2006
·
5 authors
99
citations
Sustaining Generic Medicines Markets in Europe
Journal of Generic Medicines The Business Journal for the Generic Medicines Sector
·
2006
·
2 authors
·
Open access
161
citations